Quoin Pharmaceuticals Ltd. income statement QNRX

Annual Quarterly

It recorded a net loss of $15.8 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
—
—
—
—
0
Research and development
10
+172.1%
4
+8.9%
3
+23.8%
3
+71.0%
2
+540.1%
Selling, general and administrative
6
+9.5%
6
-2.4%
6
-7.8%
7
+46.3%
4
+78.4%
Pretax income
-16
—
—
—
—
Net income
-16
-76.3%
-9
-3.2%
-9
+7.4%
-9
+56.3%
-21
Basic EPS
—
—
—
—
-0.01
Diluted EPS
—
—
—
—
-0.01
Weighted average shares, basic
—
—
—
—
1,585
Weighted average shares, diluted
—
—
—
—
1,585
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
QNRX (Nasdaq)
Incorporated in
Israel
Headquarters
Ashburn, VA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1671502
Former names
Quoin Pharmaceuticals, Ltd. (until Sep 1, 2026); Cellect Biotechnology Ltd. (until Oct 15, 2021); Cellect Biomed Ltd. (until Jul 7, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.